It’s been five months since the coronavirus pandemic ripped off the economies of countries and sabotaged the normal life of people across the globe. The much-needed thing of an hour is the potential COVID-19 vaccine.
According to the World Health Organisation (WHO), some 170 Covid-19 vaccines are in development around the world.
India may adopt a more pragmatic approach towards vaccinating its large population against covid-19 as the widening fiscal deficit and lower revenues will likely put pressure on government resources for a nationwide vaccination exercise, according to experts.
Candidates for COVID-19 vaccine:
Among the first vaccine candidates to start the final round of testing is one developed by the University of Oxford and AstraZeneca PLC. Also far along are experimental shots from Pfizer Inc. and its partner BioNTech SE, as well as Moderna Inc. AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker’s COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a possible fast-track approval from the United States.
Oxford Biomedica was among AstraZeneca’s initial partners when they teamed up in May to produce the vaccine and Tuesday’s deal could be further expanded by another year and a half into 2022 and 2023, Oxford said.
US President Donald Trump on Tuesday has announced that the vaccine for coronavirus being developed by AstraZeneca NSE 1.12 % has reached phase three clinical trials in the country and is very close to being finalised for approval.
Biotech’s coronavirus vaccine candidate CoronaVac was recently approved for emergency use as part of a programme in China to vaccinate high-risk groups such as medical staff. China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), also said it had obtained emergency use approval for a coronavirus vaccine candidate in social media platform WeChat last Sunday. State media Xinhua reported late on Friday that two vaccine candidates were approved in June for the emergency use program launched in July, without identifying the specific products.
China-based CanSino Biologics is set to launch a Phase III clinical trial of its Covid-19 vaccine candidate, Ad5-nCOV, in Saudi Arabia soon. Last month, the company was in discussions with Russia, Brazil, Chile, and Saudi to conduct a Phase III trial of the potential vaccine. The vaccine is made up of a harmless cold virus known as adenovirus type-5 (Ad5) to deliver genetic material from the coronavirus into the body. It was developed in collaboration with China’s military research unit.
China-based Sinopharm has commenced a Phase III clinical trial of its Covid-19 vaccine candidate at the Bahrain International Exhibition and Convention Centre (BIECC). The trial in UAE is being conducted by Sinopharm’s China National Biotec Group (CNBG) in alliance with the Abu Dhabi Government and artificial intelligence firm G42 Healthcare.